Atara Biotherapeutics Inc.
ATRA
NGS
Sector: Healthcare
Industry: Biotechnology
3.84
USD
0.51
(15.32%)
Optionable: Yes Market Cap: 314 M 90-day average vol: 2,714,184
Previous close: 3.33 Open: 3.42 Bid: 3.89 Ask: 3.89
52 week range
2.83 20.04
Last updated: Thursday 29th September 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Financials
ATRA Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 M |
| Cost of sales | 0 | -4000 | -532000 | -4 M | -3 M | -2 M | -2 M | -6 M | -9 M | -11 M |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 M |
| Selling Gen & administrative expense | 834000 | 4 M | 13 M | 17 M | 25 M | 40 M | 70 M | 80 M | 64 M | 79 M |
| Research & development expense | 241000 | 5 M | 15 M | 42 M | 57 M | 81 M | 167 M | 216 M | 245 M | 282 M |
| Operating income | -1 M | -9 M | -28 M | -58 M | -81 M | -122 M | -237 M | -296 M | -309 M | -340 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -3 M | 0 | 0 | -4 M | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income (EBT) | -4 M | -9 M | -28 M | -57 M | -79 M | -120 M | -231 M | -291 M | -307 M | -340 M |
| Income taxes | 17000 | 170000 | -25000 | -9000 | 10000 | -14000 | -44000 | 12000 | 15000 | 46000 |
| Net income from total operations | -4 M | -9 M | -28 M | -57 M | -79 M | -119 M | -231 M | -291 M | -307 M | -340 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -4 M | -9 M | -28 M | -57 M | -79 M | -119 M | -231 M | -291 M | -307 M | -340 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -4 M | -9 M | -28 M | -57 M | -79 M | -119 M | -231 M | -291 M | -307 M | -340 M |
| Depreciation | 0 | 4000 | 532000 | 4 M | 3 M | 2 M | 2 M | 6 M | 9 M | 11 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -1 M | -9 M | -28 M | -58 M | -81 M | -121 M | -233 M | -289 M | -301 M | -331 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.3 | -1.28 | -5.62 | -2.24 | -2.75 | -4 | -5.27 | -5.67 | -4.15 | -3.63 |
| Diluted EPS total | -0.3 | -1.28 | -5.62 | -2.24 | -2.75 | -4 | -5.27 | -5.67 | -4.15 | -3.63 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today